Phase 3 Recruiting Network
This phase III trial compares the effect of adding panitumumab to standard chemotherapy (with nanoliposomal Irinotecan, leucovorin, and 5-fluorouracil \[5-FU\] or irinotecan, leucovorin, and 5-FU or nab-paclitaxel and gemcitabine) versus s…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT06998940
Sites in Arkansas: - Highlands Oncology Group - Fayetteville — Fayetteville, Arkansas
- NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro — Jonesboro, Arkansas
- Highlands Oncology Group - Rogers — Rogers, Arkansas
- Highlands Oncology Group — Springdale, Arkansas
Phase 2, Phase 3 Recruiting Industry
Study to investigate the efficacy, safety and tolerability of systemic chemotherapy plus ponsegromab versus systemic chemotherapy plus placebo for the first-line treatment in adult participants with cachexia and metastatic pancreatic ducta…
Sponsor: Pfizer
NCT ID: NCT06989437
Sites in Arkansas: - Central Arkansas Radiation Therapy Institute, dba CARTI — Bryant, Arkansas
- Central Arkansas Radiation Therapy Institute, dba CARTI — Conway, Arkansas
- CARTI Cancer Center — Little Rock, Arkansas
- Central Arkansas Radiation Therapy Institute, dba CARTI — North Little Rock, Arkansas
- Central Arkansas Radiation Therapy Institute, dba CARTI — Pine Bluff, Arkansas
Phase 3 Recruiting Industry
Pancreatic cancer is difficult to diagnose early. By the time people have been diagnosed, the cancer has usually spread to other parts of the body (metastatic). The standard treatment is chemotherapy, but other treatments are needed to imp…
Sponsor: Astellas Pharma Global Development, Inc.
NCT ID: NCT07409272
Sites in Arkansas: - Mercy Cancer Center — Fort Smith, Arkansas
Phase 2, Phase 3 Recruiting Industry
The study is a randomized, double-blind, placebo-controlled, multicenter study of standard treatment with nab-paclitaxel and gemcitabine with or without SBP-101 in subjects previously untreated for metastatic pancreatic ductal adenocarcino…
Sponsor: Panbela Therapeutics, Inc.
NCT ID: NCT05254171
Sites in Arkansas: - Genesis Cancer and Blood Institute (SCRI) — Hot Springs, Arkansas
Phase 2 Recruiting NIH
This phase II trial investigates how well the addition of olaparib following completion of surgery and chemotherapy works in treating patients with pancreatic cancer that has been surgically removed (resected) and has a pathogenic mutation…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04858334
Sites in Arkansas: - Mercy Hospital Fort Smith — Fort Smith, Arkansas
- CHI Saint Vincent Cancer Center Hot Springs — Hot Springs, Arkansas
- NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro — Jonesboro, Arkansas
Phase 2 Recruiting Network
This phase II trial studies the effect of capecitabine and temozolomide after surgery in treating patients with high-risk well-differentiated pancreatic neuroendocrine tumors. Chemotherapy drugs, such as capecitabine and temozolomide, work…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT05040360
Sites in Arkansas: - Mercy Hospital Fort Smith — Fort Smith, Arkansas
- CARTI Cancer Center — Little Rock, Arkansas
Phase 2 Recruiting Academic/Other
This phase II study evaluates how well pemigatinib works for the treatment of adult patients with pancreatic cancer that has spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or has s…
Sponsor: Sameek Roychowdhury
NCT ID: NCT06906562
Sites in Arkansas: - Ohio State University-Telemedicine — Hot Springs, Arkansas
Phase 1, Phase 2 Recruiting Industry
This clinical trial is evaluating a drug called ART0380 in participants with advanced or metastatic solid tumors. The main goals of this study are to: * Find the recommended dose of ART0380 that can be given safely to participants alone an…
Sponsor: Artios Pharma Ltd
NCT ID: NCT04657068
Sites in Arkansas: - University of Arkansas - Winthrop P. Rockefeller Cancer Institute — Little Rock, Arkansas
Phase 2 Recruiting Network
The prognosis for patients with localized pancreatic adenocarcinoma who are not surgical candidates is poor. Patients characterized as having "borderline resectable" disease treated with preoperative chemo-radiotherapy fair somewhat better…
Sponsor: Proton Collaborative Group
NCT ID: NCT02598349
Sites in Arkansas: - Proton Center of Arkansas — Little Rock, Arkansas
Phase 1, Phase 2 Recruiting Academic/Other
By doing this study, it is the hope to learn whether an injection of the measles, mumps, rubella (MMR) vaccine developed by Merck \& Co. (Merck's M-M-R® II) into the tumor is safe and effective in making the tumor smaller.
Sponsor: University of Arkansas
NCT ID: NCT07539155
Sites in Arkansas: - University of Arkansas for Medical Sciences — Little Rock, Arkansas
Phase 1 Recruiting Industry
This trial will look at a drug called sigvotatug vedotin (SGN-B6A) alone and with pembrolizumab, with or without chemotherapy, to find out whether it is safe for people who have solid tumors. It will study sigvotatug vedotin to find out wh…
Sponsor: Seagen, a wholly owned subsidiary of Pfizer
NCT ID: NCT04389632
Sites in Arkansas: - Highlands Oncology Group — Fayetteville, Arkansas
- Highlands Oncology Group — Rogers, Arkansas
- Highlands Oncology Group — Springdale, Arkansas
Recruiting Network
The purpose of this study is to compare two approaches for monitoring pancreatic cysts as well as to identify associated biomarkers. The study doctors want to compare more frequent monitoring versus less frequent monitoring as well as iden…
Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT04239573
Sites in Arkansas: - Baptist Health Medical Center - Little Rock — Little Rock, Arkansas
- University of Arkansas for Medical Sciences — Little Rock, Arkansas
Recruiting Academic/Other
This study evaluates cancer-related weight and muscle mass loss, symptoms, and physical function (cachexia) in patients undergoing treatment for colorectal, lung, or pancreatic cancer that cannot be removed by surgery (unresectable) or is …
Sponsor: University of Rochester
NCT ID: NCT06073431
Sites in Arkansas: - Mercy Hospital Fort Smith — Fort Smith, Arkansas
Recruiting Industry
The purpose of this observational study is to collect clinical information, blood, and tumor tissue samples from participants diagnosed with stage I, stage II, or operable stage III cancer in select solid tumors. The information collected …
Sponsor: Paradigm Health
NCT ID: NCT06605404
Sites in Arkansas: - CARTI — Little Rock, Arkansas
- Highlands Oncology Group (HOG) — Springdale, Arkansas
Recruiting Industry
The purpose of ORACLE is to demonstrate the ability of a novel ctDNA assay developed by Guardant Health to detect recurrence in individuals treated for early-stage solid tumors. It is necessary that ctDNA test results are linked to clinica…
Sponsor: Guardant Health, Inc.
NCT ID: NCT05059444
Sites in Arkansas: - Genesis Cancer Center — Hot Springs, Arkansas